ISRCTN32042139 https://doi.org/10.1186/ISRCTN32042139

# Dose-ranging study of SCH34117 in the treatment of patients with seasonal allergic rhinitis

| | | |
|---|---|---|
| **Submission date**<br>02/08/2002 | **Recruitment status**<br>No longer recruiting | [_] Prospectively registered<br>[_] Protocol<br>[_] Statistical analysis plan<br>[X] Results<br>[_] Individual participant data |
| **Registration date**<br>02/08/2002 | **Overall study status**<br>Completed | |
| **Last Edited**<br>06/09/2007 | **Condition category**<br>Respiratory | |

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
MD Heribert Staudinger

**Contact details**
Medical officer
Schering-Plough Research Institute (SPRI)
2015 Galloping Hill Road, K-15-4
Kenilworth
United States of America
NJ 07033-0530

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**
C98-001

# Study information

### Scientific Title

### Study objectives
Not provided at time of registration

### Ethics approval required
Old ethics approval format

### Ethics approval(s)
Not provided at time of registration

### Study design
Randomised controlled trial

### Primary study design
Interventional

### Secondary study design
Randomised controlled trial

### Study setting(s)
Hospital

### Study type(s)
Treatment

### Participant information sheet

### Health condition(s) or problem(s) studied
Seasonal allergic rhinitis

### Interventions
Patients randomly assigned once-daily (QD) SCH34117 at doses of 2.5, 5, 7.5, 10, or 20 mg versus placebo for two weeks.

### Intervention Type
Drug

### Phase
Not Specified

### Drug/device/biological/vaccine name(s)
SCH34117

### Primary outcome measure
Not provided at time of registration

### Secondary outcome measures
Not provided at time of registration

### Overall study start date
01/04/1998

### Completion date
01/06/1998

## Eligibility

### Key inclusion criteria
Subjects 12 years or older with a two-year documented history of seasonal allergic rhinitis and otherwise in good health

### Participant type(s)
Patient

### Age group
Not Specified

### Sex
Not Specified

### Target number of participants
1026

### Key exclusion criteria
Not provided at time of registration

### Date of first enrolment
01/04/1998

### Date of final enrolment
01/06/1998

## Locations

### Countries of recruitment
United States of America

### Study participating centre
### Medical officer
Kenilworth
United States of America
NJ 07033-0530

# Sponsor information

**Organisation**
Schering-Plough Research Institute (SPRI) (USA)

**Sponsor details**
2015 Galloping Hill Road, K-15-4
Kenilworth
United States of America
NJ 07033-0530

**Sponsor type**
Industry

**Website**
http://www.schering-plough.com/rd/rd02_research.html

**ROR**
https://ror.org/02891sr49

# Funder(s)

**Funder type**
Industry

**Funder Name**
Schering-Plough Research Institute (SPRI) (USA)

# Results and Publications

**Publication and dissemination plan**
Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**
Not provided at time of registration

**Study outputs**

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|

| | | | | |
|---|---|---|---|---|
| Results article | Results | 05/08/2002 | Yes | No |